ABSTRACT IL-27 bridges innate and adaptive immunity by modulating cytokine production from myeloid cells and regulating Th cell differentiation. During bacterial infection, TLR4 triggering by LPS induces IL-27 production by monocytes and macrophages. We have previously shown that IL-27 can prime monocytes for LPS responsiveness by enhancing TLR4 expression and intracellular signaling. If unregulated, this could result in damaging inflammation, whereas on the other hand, this may also provide greater responses by inflammatory processes induced in response to bacterial pathogens. A key process in finetuning inflammatory responses is activation of the inflammasome, which ultimately results in IL-1b production. Herein, we investigated the molecular mechanisms by which IL-27 modulates LPS-induced IL-1b secretion in monocytes and macrophages. We found that when delivered simultaneously with LPS, IL-27 augments activation of caspase-1 and subsequent release of IL-1b. Furthermore, we determined that IL-27 primes cells for enhanced IL-1b production by up-regulating surface expression of TLR4 and P2X purinoceptor 7 (P2X7) for enhanced LPS and ATP signaling, respectively. These findings provide new evidence that IL-27 plays an important role in the proinflammatory capacity of monocytes and macrophages via enhancing IL-1b secretion levels triggered by dual LPS-ATP stimulation.
Introduction
IL-27 is a heterodimeric cytokine composed of p28 and EBI3 subunits [1] [2] [3] [4] . IL-27R is also heterodimeric, composed of IL27Ra (WSX-1), unique for binding IL-27, and gp130, a signaling subunit shared with IL-6 [5, 6] . In monocytes and macrophages, IL-27 activates JAK/STAT signaling via STAT1 [6] and STAT3 [7, 8] . IL-27-mediated effects are also modulated by the suppressor of cytokine signaling 3 protein, which negatively regulates STAT3 activation [9] [10] [11] . IL-27 participates in Th cell differentiation by supporting Th1 cell development and IFN-g production and by blocking Th17 development [4, 12] . Recent investigations have sparked interest in IL-27 as an inducer of myriad proinflammatory responses. Indeed, evidence supports a role for IL-27 in the activation of monocytic cells, including upregulation of proinflammatory cytokine and chemokine production [8, [13] [14] [15] . Inflammatory agents, such as LPS, induce the production of IL-27 subunits, p28 and EBI3, which are predominantly expressed by monocytes/macrophages and dendritic cells to form the bioactive IL-27 cytokine [4, 16] .
During inflammation, monocytes and macrophages secrete high levels of proinflammatory cytokines in response to bacterial components recognized by TLRs. Of these responses, TLR4 signaling, triggered by LPS from Gram-negative bacteria, is a key mediator of inflammatory cytokine production, including secretion of IL-27 [1, 17] . Critical inflammatory processes, triggered by LPS, include inflammasome activation, resulting in caspase-1-dependent cleavage of pro-IL-1b to produce active IL-1b [18, 19] . Both inflammasome formation and subsequent IL-1b production are induced by TLR4 engagement [20] . IL-1b activates and recruits immune cells to drive inflammation; however, uncontrolled IL-1b expression causes excessive inflammation and tissue damage [21] . Of the inflammasomes identified, the NLRP3 and NLRC4 inflammasomes are well characterized [22] . NLRP3 or NLRC4 can complex with ASC and procaspase-1 to induce IL-1b cleavage and secretion [18, [22] [23] [24] [25] . Activation of the NLRP3 inflammasome can be modulated by two signals: Signal 1, from LPS/TLR4 ligation, up-regulates expression of inflammasome components (NLRP3, ASC, procaspase-1), whereas Signal 2, provided by ATP, nigericin, alum crystals, or other TLR agonists, activates the inflammasome by cleavage of procaspase-1 into active caspase-1 [18, [26] [27] [28] . Upon ligation of ATP with its receptor P2X purinoceptor 7 (P2X7), pannexin-1 hemichannel pore formation occurs, resulting in potassium efflux from the cell [29] [30] [31] [32] . The change in ion gradient leads to inflammasome oligomerization, mediating autolytic cleavage of caspase-1 and consequent cleavage of pro-IL-1b for release of biologically active IL-1b [33, 34] .
Our previous work demonstrated that IL-27 induces a proinflammatory cytokine profile in nonactivated (resting) primary human monocytes and can enhance LPS-mediated proinflammatory responses via up-regulation of TLR4 expression [8, 13] . In this study, we demonstrate a key role for IL-27 in LPSinduced IL-1b production, where experiments with murine BMDMs deficient for the IL-27R show reduced IL-1b production in response to stimulation with LPS followed by ATP. Furthermore, we demonstrate that simultaneous stimulation of IL-27 and LPS, followed by ATP treatment, augments NLRP3-and P2X7-dependent IL-1b secretion in human monocytic cells. Taken together, our data show that IL-27 is required for optimal LPSinduced IL-1b production and that exogenous IL-27 further enhances the LPS response, highlighting a novel role for IL-27 in the regulation of innate immune responses.
MATERIALS AND METHODS

Cell culture and reagents
CD14-THP-1 cells were kindly provided by Dr. Richard Ulevitch (The Scripps Research Institute, La Jolla, CA, USA). Cells were cultured in RPMI (Thermo Fisher Scientific, Waltham, MA, USA), supplemented with 10% FBS (GE Healthcare Life Sciences Hyclone Laboratories, Logan, UT, USA) and G418 (BioShop Canada, Burlington, Ontario, Canada). Recombinant human and murine IL-27 was purchased from R&D Systems (Minneapolis, MN, USA) and eBioscience (San Diego, CA, USA), respectively. LPS from Escherichia coli 0111:B4 was purchased from Sigma-Aldrich (St. Louis, MO, USA). ATP was purchased from BioShop Canada. Nigericin and alum crystals were purchased from InvivoGen (San Diego, CA, USA). FMK, glybenclamide, and CRID3 sodium salt (MCC 950) were purchased from R&D Systems. Probenecid was purchased from Santa Cruz Biotechnology (Dallas, TX, USA). Molecular Probes YO-PRO-1 iodide (491/509) was purchased from Thermo Fisher Scientific. Cell death in the presence of inhibitors was equivalent to cells cultured in medium alone (#10%), as measured by propidium iodide staining and flow cytometry (Sigma-Aldrich).
BMDM isolation
Murine BMDMs were cultured as described in detail elsewhere [35] . IL27Ra 2/2 mice were backcrossed onto C57BL/6 mice, and C57BL/6 mice were used as controls [36, 37] . In brief, femurs and tibias from WT C57BL/6 and IL-27Ra 2/2 mice were collected, and the marrow was flushed with PBS.
RBCs were lysed with a lysis buffer (1.66% w/v ammonium chloride) for 5 min. After several washing steps with PBS, the cells were cultured in 6-well tissue-culture plates (3-5 3 10 6 cells/well) in conditioned medium, consisting of RPMI containing 10% FBS and 20% of L929 supernatant as a source of M-CSF. After 3 d, the nonadherent cells were removed, and fresh medium was added. The medium was changed every 2 d, and BMDM cells were harvested on d 7. BMDMs were $95% pure, as determined by F4/80 staining and flow cytometry. 
Monocyte isolation
Statistical analysis
Significance was calculated on GraphPad Prism 6 using an unpaired, 2-tailed t test over multiple repeated experiments between specified groups or Wilcoxon signed-rank test for comparisons with medium fold change given a hypothetical mean of 1.0. (Fig. 1A) . Furthermore, to investigate the potential requirement for endogenously produced IL-27 in response to LPS in IL-1b production, BMDMs from WT and IL-27Ra
RESULTS
IL-27 is required for optimal IL-1b secretion
2/2 mice were treated with LPS (Signal 1), followed by ATP treatment (Signal 2) at various time points. In both WT and IL27Ra 2/2 cells, LPS-induced IL-1b production was detected at relatively low levels (Fig. 1B) . LPS-induced IL-27 production was observed in both cell types (data not shown). In cells exposed to LPS and subsequently treated with ATP, we observed markedly enhanced IL-1b production. Most striking was the observation that ATP-induced IL-1b secretion was significantly reduced in or at least three CD14-THP-1-independent experiments. Error bars indicate SD of technical replicates. *P # 0.05; **P # 0.01; ****P # 0.0001, unpaired, 2-tailed t test.
IL-27Ra
2/2 BMDM compared with WT at all time-points tested (Fig. 1B) .
To examine the effects of IL-27 in LPS-induced IL-1b production, WT cells were treated with LPS alone, IL-27 alone, or LPS and IL-27 simultaneously for 16 h as Signal 1, followed by treatment, with or without ATP (Signal 2), for 10 h and subsequently tested for IL-1b secretion. We observed that LPS alone was able to induce a moderate level of IL-1b production. However, in the presence of LPS and IL-27 together, IL-1b production was significantly higher (Fig. 1C) . In cells given LPS (Signal 1) and ATP (Signal 2), ATP-induced IL-1b production was higher compared with cells treated with LPS alone, as expected (Fig. 1C) . Furthermore, simultaneous treatment of cells with LPS and IL-27 resulted in a striking increase in ATP-induced IL-1b secretion compared with cells treated with only LPS and ATP (Fig. 1C) . Taken together, these data demonstrate that BMDMs produce greater amounts of IL-1b in response to LPS and IL-27 when given simultaneously, indicating a potential synergistic role for LPS and IL-27 in inducing IL-1b production.
To investigate if IL-27 could modulate IL-1b production in human cells, we treated CD14-THP-1 cells with LPS, IL-27, or LPS plus IL-27 for 4, 16, and 24 h. Control cells were cultured in medium alone (med) for 4, 16, or 24 h, and resulting IL-1b secretion was measured by ELISA in cell-free supernatants. Results showed that LPS alone induced IL-1b expression, whereas IL-27 alone did not. Similar to our observations in BMDMs, a statistically significant increase in IL-1b expression was observed in cells treated simultaneously with LPS and IL-27 at 16 and 24 h compared with LPS alone (Fig. 1D ). This demonstrates that exogenously added IL-27 synergistically enhances LPS-induced IL-1b production in CD14-THP-1 cells.
IL-27 enhances caspase-1-dependent LPS/ATP-mediated IL-1b production
As inflammasome formation is initiated in human monocytic cells by a secondary signal (Signal 2) provided by ATP [20, 38] , we examined the role for IL-27 in ATP-dependent, LPS-induced IL-1b expression. As we described previously [13] , IL-27 pretreatment for 16 h optimally enhances LPS signaling in primary monocytes; therefore, we maintained the 16 h treatment with IL-27 throughout all experiments. To optimize LPS/ATP treatment times, we performed time course analyses (data not shown). From this, we observed that in primary monocytes, LPS addition in the last 4 h of the 16 h IL-27 treatment, followed by a 4 h ATP treatment, resulted in maximal induction of IL-1b. In contrast, CD14-THP-1 cells exhibited maximal IL-1b production after 16 h LPS and IL-27 and 10 h ATP. Thus, primary monocytes and CD14-THP-1 were treated accordingly. As expected, in cells given medium (med; Signal 1) followed by ATP (Signal 2) no IL-1b was detected ( Fig. 2A and B) . However, we observed significant IL-1b expression in response to ATP in LPS-treated cells. Consistent with the data shown in Fig. 1D , cells pretreated with IL-27 alone showed no significant IL-1b induction, even with ATP stimulation ( Fig. 2A and B) . Despite this, we observed a striking increase in IL-1b expression in response to ATP in both cell types treated with LPS plus IL-27 compared with cells that received LPS alone ( Fig. 2A and B) . In cells that received LPS plus IL-27 as Signal 1, followed by medium, IL-1b was detected, likely as a result of the ability of LPS plus IL-27 to induce IL-1b in the absence of exogenously added ATP, as observed in Fig. 1D . Taken together, these data demonstrate that stimulation of human monocytic cells with LPS and IL-27 followed by ATP results in enhanced inflammasome activation compared with LPS/ATP alone.
As procaspase-1 cleavage and caspase-1 activity are required for IL-1b production, the caspase-1 inhibitor FMK was used to confirm the requirement for caspase-1 in our model [39] . Cells were treated with LPS, IL-27, or IL-27 for 16 h, with LPS in the final 4 h (primary monocytes), or LPS, IL-27, or LPS and IL-27 for 16 h (CD14-THP-1), followed by ATP for an additional 4 (primary monocytes) or 10 h (CD14-THP-1) in the presence or absence of FMK (20 mM). Both primary monocytes and CD14-THP-1 cells showed significantly decreased IL-1b production in the presence of FMK ( Fig. 2A and B ). This shows a requirement for caspase-1 in ATP-induced inflammasome activation upon treatment with LPS alone or LPS plus IL-27 as Signal 1.
Given that IL-1b production requires caspase-1, we investigated whether IL-27 may impact the activity of this protease. Therefore, we examined how dual stimulation with LPS and IL-27 impacts activity of caspase-1 by using a caspase-1 activity assay. We initially performed this assay in CD14-THP-1 cells; however these cells gave an unexpectedly high baseline reading (data not shown). Therefore, we performed this assay in the parental THP-1 cell line, as well as in primary human monocytes. Primary monocytes (Fig. 2C ) and THP-1 cells (Fig.  2D) were treated with IL-27 or left untreated (med) for 16 h, with LPS added during the last 4 h of these treatments, and then followed by ATP for 30 min in both cell types for optimal detection of caspase-1 activity. Caspase-1 activity was then quantified in cell-free supernatants. As expected, caspase-1 activity did not exceed baseline levels in cells that received the caspase-1 inhibitor, Ac-YVAD-CHO ( Fig. 2C and D ; gray bars). After ATP stimulation, LPS plus IL-27-treated THP-1 cells exhibited significantly higher caspase-1 activity compared with LPS alone ( Fig. 2C and D ; black bars). In cells treated with IL-27 alone, no significantly different ATP-induced caspase-1 activity was observed compared with medium controls for Signal 1. Similar trends were observed in primary human monocytes and THP-1 cells, whereby LPS plus IL-27 treatment induced greater caspase-1 activity compared with LPS treatment alone; however, these differences did not reach statistical significance in primary monocytes ( Fig. 2C and D ; black bars).
IL-27 induces elevated LPS-induced pro-IL-1b and procaspase-1 in CD14-THP-1 cells but not primary human monocytes
To investigate the mechanism used by IL-27 to enhance LPSinduced IL-1b production protein levels of pro-IL-1b, procaspase-1, NLRP3, as well as the ion hemichannel opened by ATP stimulation, pannexin-1, were measured by Western blotting. CD14-THP-1 was stimulated with LPS, IL-27, or LPS plus IL-27 for 4, 10, and 16 h, whereas primary human monocytes were treated with or without IL-27 for 16 h, with or without LPS for 4 h. Levels of pro-IL-1b and procaspase-1 were elevated in CD14-THP-1 cells stimulated for 16 h with LPS plus IL-27 compared with LPS alone ( Fig. 3A and B; left) . As expected, pro-IL-1b expression was enhanced by LPS stimulation in primary human monocytes. Surprisingly, primary monocytes stimulated with LPS plus IL-27 did not show notable differences in pro-IL-1b or procaspase-1 levels compared with LPS alone ( Fig. 3A and B; right) . However, there was a notable increase in the caspase-1 intermediate form (45 kDa band) upon IL-27 stimulation alone compared with LPS alone or LPS plus IL-27 stimulation in primary human monocytes ( Fig. 3B ; right) A more moderate effect of IL-27 alone on procaspase-1 expression levels in CD14-THP-1 cells was also observed. Levels of NLRP3 and pannexin-1 in both CD14-THP-1 cells and primary human monocytes showed no distinguishable differences among unstimulated, LPS-, IL-27-, or LPS plus IL-27-stimulated groups (Fig. 3C and D) . Of note, glycosylated pannexin-1 was observed in primary monocytes, as confirmed by endoglycosidase H treatment of cell extracts (data not shown). Thus, we detected multiple bands in monocyte extracts compared with that obtained from CD14-THP-1 cells (Fig. 3D) . Taken together, these data suggest that in CD14-THP-1 cells, IL-27-modulated LPS-induced IL-1b secretion is potentiated by up-regulation of pro-IL-1b and procaspase-1 expression; however, in primary monocytes, a different mechanism may be at play.
IL-27 enhances TLR4 and MD2 expression but does not affect CD14 expression
As levels of the LPS-binding partners, TLR4, MD2, and CD14, may contribute to enhanced LPS responsiveness and inflammasome induction, we assessed whether dual stimulation with IL-27 and LPS affected surface levels of these proteins. Primary human monocytes were stimulated with IL-27 for 16 h and LPS for the last 4 h (Fig. 4A) , whereas CD14-THP-1 cells were stimulated with LPS alone, IL-27 alone, or LPS plus IL-27 for 16 h (Fig. 4B) . LPS (100 ng/ml) for 4 h, IL-27 (100 ng/ml) for 16 h, or IL-27 for 16 h plus LPS for the final 4 h. Cells were then exposed to Signal 2: ATP (5 mM) for 30 min. Ac-YVAD-CHO caspase-1 inhibitor was used as a control, per the manufacturer's instructions. Caspase-1 activity was measured by bioluminescent luciferase activity in cell-free supernatants. Data are representative of at least four replicate experiments. Error bars indicate SD of replicate sets. *P # 0.05; **P # 0.01; ***P # 0.001; ****P # 0.0001, unpaired, 2-tailed t test.
As documented previously [13] , treatment with IL-27 alone significantly up-regulated TLR4 expression in both cell types, and likewise, LPS plus IL-27 also induced significantly greater TLR4 expression compared with LPS alone (Fig. 4A and B) . Primary human monocytes showed a very modest increase in MD2 expression in LPS plus IL-27-stimulated cells compared with medium control; however, these differences did not reach statistical significance (Fig. 4C) , whereas MD2 showed increased levels upon IL-27 or LPS plus IL-27 stimulation in CD14-THP-1 compared with medium controls (Fig. 4D) . CD14 showed no consistent changes across the different conditions (data not shown).Taken together, these data indicate that IL-27-induced TLR4 and MD2 expression likely contributes to enhanced LPS responsiveness in human monocytic cells.
IL-27-enhanced, LPS-mediated IL-1b production requires NLRP3
To confirm that the NLRP3 inflammasome is required for IL-1b production in our model, we treated cells with glybenclamide, which blocks the ATP-sensitive potassium channels required for NLRP3 inflammasome activation [29, 40] , or CRID3 sodium salt (MCC 950), which inhibits ASC oligomerization and NLRP3 inflammasome formation [41] . CD14-THP-1 cells and primary human monocytes were incubated in the presence and absence of the NLRP3 inhibitors with Signal 1 (LPS + IL-27), followed by Signal 2 (ATP) treatment. Glybenclamide and CRID3 sodium salt significantly inhibited ATP-induced IL-1b production in cells treated with LPS or LPS plus IL-27 to levels observed with the Figure 4 . IL-27 enhances LPS-induced inflammasome activation via upregulation of TLR4 and MD2 in primary human monocytes and CD14-THP-1 cells. Primary human monocytes were incubated in the presence of Signal 1: LPS (100 ng/ml) for 4 h, IL-27 (100 ng/ml) for 16 h, or IL-27 for 16 h plus LPS for the final 4 h (A and C). CD14-THP-1 cells were incubated in the presence of LPS (100 ng/ml), IL-27 (100 ng/ml), or LPS plus IL-27 for 16 h (B and D). Cells were then stained for TLR4 (A and B) or MD2 (C and D). All data sets were measured using flow cytometry and analyzed using FlowJo software, version 10.0.7r2. Cells were gated for live cells and then CD14 + monocytic cells. Lines indicate stained cells, and filled histograms represent isotype controls. Histograms are representative of six replicate experiments. Fold increase was calculated relative to medium per individual experiment and plotted for each experiment as the average fold increase. Error bars indicate SE of all replicates. *P # 0.05; **P # 0.01; ***P # 0.001; ****P # 0.0001; ns, not significant, Wilcoxon signed-rank test used for analysis relative to medium given a hypothetical value of 1.0 and unpaired, 2-tailed t test used for analysis between other groups. Signal 2 control (med) in CD14-THP-1 cells (Fig. 5A) . Likewise, in primary monocytes, LPS and LPS plus IL-27-primed monocytes showed significantly lower IL-1b production upon the addition of glybenclamide or CRID3 sodium salt compared with cells without inhibitors (Fig. 5B) . These data suggest that NLRP3-induced potassium efflux is required for LPS plus IL-27-induced IL-1b production.
IL-27-enhanced IL-1b production is dependent on the P2X7 receptor and pannexin-1-activity
As inflammasome activity can be stimulated by multiple mechanisms, we investigated if IL-27 could mediate NLRP3 inflammasome activity induced by other agonists. Therefore, we examined the impact of IL-27 treatment on nigericinmediated NLRP3 inflammasome activity [42] . We treated primary human monocytes with IL-27 for 16 h, LPS for the last 4 h, and CD14-THP-1 cells with LPS, IL-27, or both LPS plus IL-27 for 16 h, and both cell types were then stimulated with nigericin for an additional 30 min [38, 43] . As expected, stimulation of cells with LPS followed by nigericin induced IL-1b production ( Fig. 6A and B) . Interestingly, IL-27 pretreatment with LPS followed by nigericin did not show any significant difference compared with LPS and nigericin alone ( Fig. 6A and B) . This demonstrates that whereas the NLRP3 inflammasome is responsible for IL-1b induction in our model, IL-27 may be affecting a mechanism upstream of NLRP3 activation. Therefore, we decided to investigate the impact of IL-27 on expression and function of the ATP receptor, P2X7. Primary human monocytes were stimulated with IL-27 for 16 h plus LPS for the last 4 h, whereas CD14-THP-1 cells were stimulated with LPS alone, IL-27 alone, or LPS plus IL-27 for 16 h. Expression of P2X7 was analyzed by flow cytometry (Fig. 7A and B) . Both primary human monocytes and CD14-THP-1 cells showed significantly greater P2X7 surface expression in LPS plus IL-27 compared with cells stimulated with medium alone (Fig. 7A  and B) . In primary monocytes, IL-27 alone induced significantly greater P2X7 expression compared with medium or LPS alone (Fig. 7A) , whereas CD14-THP-1 cells showed enhanced P2X7 surface expression upon both LPS and LPS plus IL-27 stimulation (Fig. 7B) . These data indicate that costimulation of LPS and IL-27 up-regulates the ATP receptor in human monocytic cells-a possible novel mechanism used by IL-27 to enhance LPS-induced IL-1b production.
To investigate whether IL-27 treatment leads to increased P2X7 receptor function, we used the YO-PRO-1 iodide dye uptake assay [44] . YO-PRO-1 iodide is a nucleic acid stain that enters cells through ATP-gated pannexin-1 channels, whereby increased dye uptake correlates with greater ATP/P2X7 function and pore formation. CD14-THP-1 cells were stimulated for 16 h with LPS plus IL-27, whereas primary human monocytes were treated for 16 h with IL-27 plus LPS in the last 4 h. Cells were treated with YO-PRO-1 iodide for 15 min before measurement of Error bars indicate SD of technical replicates. *P # 0.05; **P # 0.01; ***P # 0.001, unpaired, 2-tailed t test. dye uptake. In both cell types, basal levels of dye uptake were observed upon treatment with IL-27 alone, LPS alone, or IL-27 plus LPS (Fig. 8A and B) . In response to ATP addition, in primary human monocytes, there was significantly increased YO-PRO-1 uptake in LPS plus IL-27-stimulated cells compared with LPS-treated cells (Fig. 8A) . In CD14-THP-1 cells, ATP stimulation resulted in significantly greater YO-PRO-1 dye uptake in LPS alone, IL-27 alone, and LPS plus IL-27 pretreatment compared with medium controls (Fig. 8B) . These data support a potential mechanism for IL-27 to modulate inflammasome activation via enhancement of the P2X7 receptor function.
As ATP binding of the P2X7 receptor results in opening pannexin-1 hemichannels for ion exchange [32] , we investigated the requirement of pannexin-1 in our model. Pannexin-1 pore function was inhibited using probenecid, which blocks the organic anion currents, thus abrogating P2X7 signaling [45] . Therefore, to elucidate the role of the pannexin-1/P2X7 axis in our model, we added probenecid (1 mM) concomitantly with both Signals 1 and 2. In both cell types, probenecid abrogated ATP-induced IL-1b production ( Fig. 8C and D) . Taken together, these data establish an essential role for pannexin-1 channel function in optimal IL-27-mediated, LPS-induced IL-1b production.
DISCUSSION
In this study, we demonstrated that simultaneous addition of IL-27 with LPS in vitro augments IL-1b production from human monocytes. We determined that this response was dependent on NLRP3 inflammasome and caspase-1 activation and that induction of TLR4 expression may account for enhanced LPS-induced IL-1b production. Moreover, IL-27-mediated effects on the P2X7 receptor and pannexin-1 activation are integral to the enhanced IL-1b production in our model system.
As IL-27 is produced in response to LPS stimulation [46, 47] , we reasoned that IL-27 may act in an autocrine manner to promote LPS-mediated inflammasome formation. Indeed, in WSX-1-deficient (IL-27Ra 2/2 ) BMDMs, we observed significantly lower levels of LPS/ATP-induced IL-1b secretion compared with WT BMDM. In contrast to our observations, Mascanfroni et al. [48] demonstrated that murine conventional dendritic cells, costimulated with IL-27 and LPS for 48 h, exhibited decreased inflammasome activation and IL-1b production. However, it should be noted that IL-27 function, in the context of LPS responsiveness, may depend on cell type and activation status. In particular, different APCs, such as macrophages or dendritic cells, respond differently to LPS stimulation in the absence of IL-27 signaling. In support of our data, others have shown that peritoneal macrophages from WSX-1-deficient mice exhibit decreased levels of cytokines in response to LPS/IFN-g stimulation [7] . However, dendritic cells isolated from WSX-1-deficient mice displayed enhanced TNF-a and IL-12p40 production in response to LPS stimulation [49] . In our study, decreased IL-1b secretion in IL-27Ra 2/2 BMDMs suggests that IL-27 plays a pertinent role in production of this cytokine.
To identify the mechanisms affected by exogenous IL-27 treatment of human monocytes responsible for enhanced IL-1b secretion, we examined several key steps required for inflammasome activation. Our data demonstrate a requirement for caspase-1 activation in IL-1b production in both primary monocytes and THP-1 cells. Although procaspase-1 expression was induced by IL-27, no corresponding significant changes in caspase-1 activity levels were observed. Moreover, we show that LPS plus IL-27 (Signal 1), followed by ATP (Signal 2), resulted in greater caspase-1 activity compared with LPS/ATP alone, even though protein levels of procaspase-1 remained unchanged. In primary human monocytes, the difference in caspase-1 activity levels did not reach statistical significance; however, the data follow the same trend observed in THP-1 cells. This greater caspase-1 activity represents a possible mechanism driving enhanced IL-1b production.
As IL-27 enhances LPS-induced NF-kB activation in human monocytes [13] , and NF-kB induces pro-IL-1b and NLRP3 expression [20, 50] , it is possible that dual stimulation with LPS and IL-27 up-regulates expression of these proteins. Although we show that IL-27 alone did not impact pro-IL-1b protein expression in our model, others demonstrated that IL-27 treatment of human primary monocytes resulted in enhanced levels of IL-1b mRNA [6] . We observed that costimulation of IL-27 and LPS resulted in a modest increase in pro-IL-1b expression compared with LPS alone in CD14-THP-1 cells; however, this upregulation was not observed in primary monocytes. This indicates that at least for primary monocytes, other IL-27-mediated mechanisms could modulate the capacity of the cells to produce IL-1b in response to LPS/ATP.
Previously established in our lab, IL-27 enhances TLR4 surface expression and LPS responsiveness in human monocytes [13] . As LPS signaling also requires CD14 and the scaffold protein MD2 [51] [52] [53] , we examined whether IL-27, with or without LPS, could also modulate surface expression of these proteins. In both cell types, treatment with IL-27 alone or in conjunction with LPS resulted in significantly enhanced TLR4 expression compared with LPS treatment alone. Likewise, in CD14-THP-1 cells, LPS plus IL-27 moderately upregulated MD2 surface expression compared with LPS alone. However, in primary human monocytes, no differences in MD2 levels were observed. In primary monocytes, dual stimulation with LPS and IL-27 resulted in lower TLR4 expression compared with IL-27 alone, whereas in CD14-THP-1 cells, TLR4 expression remained consistent between these 2 conditions. When LPS is complexed with CD14-TLR4-MD2, it initiates MyD88 signaling, and the complex is subsequently endocytosed to signal through the Toll/IL-1R domaincontaining adapter inducing IFN-b pathway [54, 55] . Thus, internalization of the LPS-TLR4 complex in primary monocytes may result in lower amounts of TLR4 present on the cell surface. It should also be noted that the CD14-THP-1 cells constitutively express CD14; therefore, it is possible that TLR4 expression is more stable at the cell surface, as it may be refractory to internalization. ATP as Signal 2 has been well characterized to induce NLRP3-mediated IL-1b secretion from LPS-treated cells [27, 56] . Indeed, our data demonstrate that NLRP3 induction is required for IL-1b production. However, IL-27 did not impact NLRP3 protein levels. Moreover, IL-27/LPS pretreatment was unable to enhance IL-1b production over that of LPS pretreatment alone, in response to stimulation with nigericin, another NLRP3-inflammasome activator. In contrast to ATP, nigericin is a pore-forming toxin, which triggers NLRP3 inflammasome activation in the absence of P2X7 receptor expression [57] . Therefore, we examined the effect of IL-27 on P2X7 receptor levels. Cells costimulated with LPS and IL-27 demonstrated enhanced P2X7 receptor expression that correlated with the trend of enhanced YO-PRO dye uptake compared with LPS treatment alone. Interestingly, other cytokines have been shown to play a role in P2X7 function; TNF-a increases P2X7 expression, as well as calcium ion uptake [58] . As we demonstrated previously that IL-27 enhances TNF-a expression in human monocytes [8] , it is possible that IL-27-induced intermediates, such as TNF-a, could play a role in enhancing P2X7 receptor expression and function. In primary monocytes, levels of P2X7 expression in cells treated with IL-27/LPS were slightly lower than IL-27 alone; this could be a result of endogenous LPS-induced ATP production causing P2X7 receptor internalization [59] . Further examination of P2X7 receptor levels and rates of internalization are needed to delineate the specific requirement for P2X7 in IL-27-mediated IL-1b production. Moreover, examination of endogenous ATP and P2X7 receptor levels in IL-27ra 2/2 animals is needed to provide further insight into the role of IL-27 and P2X7 receptor activation. Upon ATP/P2X7 ligation, the hemichannel pannexin-1 forms a pore, facilitating potassium efflux required for NLRP3 inflammasome activation detectable by YO-PRO-1 dye uptake [30, 32] . LPS plus IL-27 enhanced ATP-mediated YO-PRO-1 dye uptake, indicating that the pannexin-1 hemichannel function is a potential factor integral to IL-27-enhanced IL-1b production. Although expression levels of pannexin-1 were unchanged by LPS or IL-27 stimulation, treatment with the pannexin-1 inhibitor, probenecid, showed a requirement for activation of the pannexin-1 channel to elicit IL-1b secretion in our model. Taken together, our data suggest that IL-27-mediated effects on inflammasome formation require activation of the pannexin-1/ P2X7 axis.
Herein, we demonstrate a role for IL-27 in promoting inflammasome activation in response to LPS triggering, indicating that during bacterial infection, IL-27 may function to prime monocytes and macrophages to respond with an optimal inflammatory response. Thus, this work provides support for further research into the role of this cytokine in the regulation of myeloid cell responses during infection and inflammation. 
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